Efficacy of Low Dose Sugammadex in Reversal of NMB in Laparoscopic Barbaric Surgery

Assiut University180 enrolled

Overview

the investigators aimed to compare the efficacy and safety of sugammadex at doses of 1.5, 2, and 4 mg/ kg for the reversal of moderate rocuronium-induced neuromuscular blockade in laparoscopic bariatric surgery.

Patients were randomly assigned using a randomization-computer program into three groups according to the dose of sugammadex administrated (according to the IBW after T2 of TOF): Group I: patients were given 1.5 mg / kg. Group II: patients were given 2 mg / kg. Group III: patients were given 4 mg / kg.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

HEALTH_SERVICES_RESEARCH

Masking

DOUBLE

Enrollment

180

Conditions

Bariatric Patients

Interventions

sugammadex reversal of neuromuscular blockadeDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * morbidly obese patients of both sex (BMI \> 40 kg.m-2) * scheduled for elective laparoscopic bariatric surgery (gastric bypass or sleeve surgery) under general anesthesia using rocuronium for tracheal intubation and maintenance of NMB * aged between 18 and 60 years and classified as ASA II - III Exclusion Criteria: * liver and renal dysfunction, * disabling neuropsychiatric disorders, * history of stroke, brain trauma in the last 12 months * hypersensitivity to anesthetics, history of myocardial infarction, congestive heart failure * difficult tracheal intubation, and known or suspected disorder affecting NMB.

Locations (1)

South Egypt Cancer Instuite

Asyut, Egypt

Outcomes

Primary Outcomes

sugammadex time following a dose of 1.5 mg / kg of sugammadex according to IBW in comparison to 2, and 4 mg / kg,

Time frame: 2 hrs

Secondary Outcomes

extubation time

Time frame: 2 hrs

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.